Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study
Musim Alotaibi,1,2 Ahmed Ali,1,3 Duaa Bakhshwin,4 Yasser Alatawi,5 Sultan Alotaibi,6 Abdullah Alhifany,7 Badr Alharthi,2 Nasser Alharthi,2 Awatef Alyazidi,2 Yasmeen Alharthi,2 Aziza Alrafiah8 1Department of Pharmacology, King Abdulaziz University, Jeddah City, Kingdom of Saudi Arabia; 2Department of...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-09-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/effectiveness-and-safety-of-favipiravir-compared-to-hydroxychloroquine-peer-reviewed-fulltext-article-IJGM |
| _version_ | 1818729119057182720 |
|---|---|
| author | Alotaibi M Ali A Bakhshwin D Alatawi Y Alotaibi S Alhifany A Alharthi B Alharthi N Alyazidi A Alharthi Y Alrafiah A |
| author_facet | Alotaibi M Ali A Bakhshwin D Alatawi Y Alotaibi S Alhifany A Alharthi B Alharthi N Alyazidi A Alharthi Y Alrafiah A |
| author_sort | Alotaibi M |
| collection | DOAJ |
| description | Musim Alotaibi,1,2 Ahmed Ali,1,3 Duaa Bakhshwin,4 Yasser Alatawi,5 Sultan Alotaibi,6 Abdullah Alhifany,7 Badr Alharthi,2 Nasser Alharthi,2 Awatef Alyazidi,2 Yasmeen Alharthi,2 Aziza Alrafiah8 1Department of Pharmacology, King Abdulaziz University, Jeddah City, Kingdom of Saudi Arabia; 2Department of Pharmacy, King Faisal Medical Complex, Taif City, Kingdom of Saudi Arabia; 3Department of Pharmaceutics, Assiut University, Assiut City, Egypt; 4Department of Pharmacotherapy and Outcomes Science, King Abdulaziz University, Jeddah City, Kingdom of Saudi Arabia; 5Department of Pharmacy Practice, University of Tabuk, Tabuk City, Kingdom of Saudi Arabia; 6Department of Pharmacy, King Abdul-Aziz Medical, Jeddah City, Kingdom of Saudi Arabia; 7Department of Clinical Pharmacy College of Pharmacy, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia; 8Department of Medical Laboratory Technology, King Abdulaziz University, Jeddah City, Kingdom of Saudi ArabiaCorrespondence: Aziza Alrafiah P.O Box 80200, Jeddah, 21589, Kingdom of Saudi ArabiaTel +966 126401000 Ext. 23495Fax +966 126401000 Ext. 21686Email aalrafiah@kau.edu.saBackground: Coronavirus disease (COVID-19) is an infectious disease due to SARS-COV-2. Patients with risk factors are vulnerable to severe morbidity and mortality. Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments.Objective: To investigate the effectiveness and safety of FPV compared to HCQ in patients with COVID-19 as the standard of care approved by the national protocol there.Methods: This is a retrospective cohort study on patients with COVID-19 who were administered either FPV or HCQ at King Faisal Medical Complex, Taif, Saudi Arabia, from June 2020 to August 2020.Results: In total, 508 patients were included in the analysis. Patients were categorized into three groups by medication. Patients enrolled in this study were 244 (55.8%) on FPV, 193 (44.2%) on HCQ and 71 (13.81%) on neither medication. Patients who received FPV had higher age and greater comorbidity. Most of the patients were discharged on day 14 (n = 303, 59.6%), 26 (36.6%) in neither med, 154 (63.1%) in FPV and 123 (63.7%) in HCQ groups with significant difference between groups (P < 0.0001). Mortality rate was 8.2% (n = 20) in FPV and 7.3% (n = 14) in HCQ groups with significant difference between groups (P = 0.048). Regarding drug safety, 19.7% of patients treated with FPV vs 7.8% HCQ have adverse effects with significant difference between groups (P < 0.0001). Most of the side effects were increase ALT and AST. Meanwhile, prolonged Q-T interval was reported only in the HCQ group (2.6%). From Cox regression modeling, only mechanical ventilation due to Covid 19 was predictive for mortality (HR: 16.598, 95% CI: 7.095– 38.828, P < 0.0001). Meanwhile, there was no significant difference in the prediction of discharge of FPV (vs HCQ) (HR: 0.933, 95% CI: 0.729– 1.195, P = 0.5843), predictors of mortality were HCQ (vs FPV) (HR: 2.3, 95% CI: 0.994– 5.487, P = 0.0518). Kaplan–Meier survival curves showed improved survival time and discharged time among patients in the HCQ versus FPV group with an insignificant difference between them (P = 0.85, P = 0.06, respectively).Conclusion: The present study concluded that FPV and HCQ showed comparable efficacy in decrease mortality and oxygen requirements. FPV likely has a more favorable safety profile regarding cardiac toxicity. A randomized clinical trial with large patient numbers is recommended to confirm the effectiveness of these drugs in COVID-19 patients.Keywords: coronavirus disease, COVID-19, favipiravir, hydroxychloroquine, mortality, risk factors |
| first_indexed | 2024-12-17T22:40:49Z |
| format | Article |
| id | doaj.art-9187e63e6ce9491eb638506b375fead9 |
| institution | Directory Open Access Journal |
| issn | 1178-7074 |
| language | English |
| last_indexed | 2024-12-17T22:40:49Z |
| publishDate | 2021-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj.art-9187e63e6ce9491eb638506b375fead92022-12-21T21:29:56ZengDove Medical PressInternational Journal of General Medicine1178-70742021-09-01Volume 145597560668769Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective StudyAlotaibi MAli ABakhshwin DAlatawi YAlotaibi SAlhifany AAlharthi BAlharthi NAlyazidi AAlharthi YAlrafiah AMusim Alotaibi,1,2 Ahmed Ali,1,3 Duaa Bakhshwin,4 Yasser Alatawi,5 Sultan Alotaibi,6 Abdullah Alhifany,7 Badr Alharthi,2 Nasser Alharthi,2 Awatef Alyazidi,2 Yasmeen Alharthi,2 Aziza Alrafiah8 1Department of Pharmacology, King Abdulaziz University, Jeddah City, Kingdom of Saudi Arabia; 2Department of Pharmacy, King Faisal Medical Complex, Taif City, Kingdom of Saudi Arabia; 3Department of Pharmaceutics, Assiut University, Assiut City, Egypt; 4Department of Pharmacotherapy and Outcomes Science, King Abdulaziz University, Jeddah City, Kingdom of Saudi Arabia; 5Department of Pharmacy Practice, University of Tabuk, Tabuk City, Kingdom of Saudi Arabia; 6Department of Pharmacy, King Abdul-Aziz Medical, Jeddah City, Kingdom of Saudi Arabia; 7Department of Clinical Pharmacy College of Pharmacy, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia; 8Department of Medical Laboratory Technology, King Abdulaziz University, Jeddah City, Kingdom of Saudi ArabiaCorrespondence: Aziza Alrafiah P.O Box 80200, Jeddah, 21589, Kingdom of Saudi ArabiaTel +966 126401000 Ext. 23495Fax +966 126401000 Ext. 21686Email aalrafiah@kau.edu.saBackground: Coronavirus disease (COVID-19) is an infectious disease due to SARS-COV-2. Patients with risk factors are vulnerable to severe morbidity and mortality. Favipiravir (FPV) and hydroxychloroquine (HCQ) are considered possible COVID-19 treatments.Objective: To investigate the effectiveness and safety of FPV compared to HCQ in patients with COVID-19 as the standard of care approved by the national protocol there.Methods: This is a retrospective cohort study on patients with COVID-19 who were administered either FPV or HCQ at King Faisal Medical Complex, Taif, Saudi Arabia, from June 2020 to August 2020.Results: In total, 508 patients were included in the analysis. Patients were categorized into three groups by medication. Patients enrolled in this study were 244 (55.8%) on FPV, 193 (44.2%) on HCQ and 71 (13.81%) on neither medication. Patients who received FPV had higher age and greater comorbidity. Most of the patients were discharged on day 14 (n = 303, 59.6%), 26 (36.6%) in neither med, 154 (63.1%) in FPV and 123 (63.7%) in HCQ groups with significant difference between groups (P < 0.0001). Mortality rate was 8.2% (n = 20) in FPV and 7.3% (n = 14) in HCQ groups with significant difference between groups (P = 0.048). Regarding drug safety, 19.7% of patients treated with FPV vs 7.8% HCQ have adverse effects with significant difference between groups (P < 0.0001). Most of the side effects were increase ALT and AST. Meanwhile, prolonged Q-T interval was reported only in the HCQ group (2.6%). From Cox regression modeling, only mechanical ventilation due to Covid 19 was predictive for mortality (HR: 16.598, 95% CI: 7.095– 38.828, P < 0.0001). Meanwhile, there was no significant difference in the prediction of discharge of FPV (vs HCQ) (HR: 0.933, 95% CI: 0.729– 1.195, P = 0.5843), predictors of mortality were HCQ (vs FPV) (HR: 2.3, 95% CI: 0.994– 5.487, P = 0.0518). Kaplan–Meier survival curves showed improved survival time and discharged time among patients in the HCQ versus FPV group with an insignificant difference between them (P = 0.85, P = 0.06, respectively).Conclusion: The present study concluded that FPV and HCQ showed comparable efficacy in decrease mortality and oxygen requirements. FPV likely has a more favorable safety profile regarding cardiac toxicity. A randomized clinical trial with large patient numbers is recommended to confirm the effectiveness of these drugs in COVID-19 patients.Keywords: coronavirus disease, COVID-19, favipiravir, hydroxychloroquine, mortality, risk factorshttps://www.dovepress.com/effectiveness-and-safety-of-favipiravir-compared-to-hydroxychloroquine-peer-reviewed-fulltext-article-IJGMcoronavirus diseasecovid-19favipiravirhydroxychloroquinemortalityrisk factors |
| spellingShingle | Alotaibi M Ali A Bakhshwin D Alatawi Y Alotaibi S Alhifany A Alharthi B Alharthi N Alyazidi A Alharthi Y Alrafiah A Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study International Journal of General Medicine coronavirus disease covid-19 favipiravir hydroxychloroquine mortality risk factors |
| title | Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study |
| title_full | Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study |
| title_fullStr | Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study |
| title_full_unstemmed | Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study |
| title_short | Effectiveness and Safety of Favipiravir Compared to Hydroxychloroquine for Management of Covid-19: A Retrospective Study |
| title_sort | effectiveness and safety of favipiravir compared to hydroxychloroquine for management of covid 19 a retrospective study |
| topic | coronavirus disease covid-19 favipiravir hydroxychloroquine mortality risk factors |
| url | https://www.dovepress.com/effectiveness-and-safety-of-favipiravir-compared-to-hydroxychloroquine-peer-reviewed-fulltext-article-IJGM |
| work_keys_str_mv | AT alotaibim effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alia effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT bakhshwind effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alatawiy effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alotaibis effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alhifanya effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alharthib effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alharthin effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alyazidia effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alharthiy effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy AT alrafiaha effectivenessandsafetyoffavipiravircomparedtohydroxychloroquineformanagementofcovid19aretrospectivestudy |